Actinium Pharmaceuticals, Inc. (Delaware) · AMEX:ATNM

Actinium Pharmaceuticals, Inc. (Delaware) financial statements

Actinium Pharmaceuticals, Inc. (Delaware)'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue90.0K081.0K1.03M1.14M622.0K0000
Cost of revenue811.0K790.0K699.0K900.0K447.0K420.1K50.7K55.9K77.5K
Gross profit90.0K-811.0K81.0K1.03M620.0K-447.0K-420.1K-50.7K-55.9K-77.5K
Research and development21.1M30.0M38.7M23.1M18.0M16.1M16.6M17.1M17.7M17.8M
Selling, general and administrative15.2M12.1M13.3M12.0M8.08M6.31M5.52M6.73M9.15M9.27M
Operating income-36.2M-42.1M-51.9M-34.1M-25.0M-22.4M-22.1M-23.8M-26.9M-26.8M
Depreciation and amortization173.0K197.0K207.0K699.0K524.0K447.0K420.0K50.7K55.9K77.5K
EBITDA-36.1M-41.9M-51.7M-33.4M-24.4M-21.9M-21.7M-23.8M-26.9M-26.8M
Interest expense1.09M190.0K00173.4K5.43K5.01K
Income before tax-33.3M-38.2M-48.8M-33.0M-24.8M-22.2M-21.9M-23.7M-26.6M-24.3M
Income tax622.1K-1.09M-190.0K-178.0K-172.0K173.4K-310.0K5.01K
Net income-33.9M-38.2M-48.8M-33.0M-24.8M-22.2M-21.9M-23.7M-26.6M-24.3M
Earnings per share, basic-1.09-1.27-1.83-1.37-1.20-1.83-4.40-0.22-0.40-0.50
Earnings per share, diluted-1.09-1.27-1.83-1.37-1.20-1.83-4.40-0.22-0.40-0.50

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents48.0M72.9M76.7M108.9M77.8M63.6M9.25M13.7M17.4M20.5M
Short-term investments35.0K
Current assets49.4M74.5M78.3M110.9M79.7M64.9M10.1M14.3M17.8M22.4M
Property, plant and equipment295.0K364.0K550.0K604.0K340.0K312.0K113.0K118.8K57.4K88.5K
Goodwill100.0K
Total assets51.8M76.9M81.4M114.2M80.4M66.4M11.7M14.9M18.3M22.5M
Accounts payable7.57M7.95M10.1M5.54M4.34M4.60M5.81M4.65M4.19M
Current liabilities7.97M8.15M8.49M10.6M6.84M4.77M5.34M6.06M4.67M4.52M
Long-term debt900.0K
Total debt1.69M1.57M2.11M2.58M310.0K738.0K1.43M262.6K
Total liabilities43.9M44.1M45.1M47.7M6.84M5.08M6.03M6.08M4.67M4.52M
Shareholders' equity7.83M32.8M36.4M66.5M73.5M61.3M5.64M8.81M13.7M18.0M
Shares outstanding31.2M31.2M27.6M25.7M22.1M17.5M5.49M115.7M80.1M55.8M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-24.6M-33.1M-47.3M8.64M-20.9M-21.6M-21.5M-20.6M-21.6M-20.8M
Capital spending-104.0K-11.0K-153.0K-366.0K-133.0K-253.0K-64.0K-96.1K-24.7K-60.0K
Free cash flow-24.7M-33.1M-47.5M8.28M-21.0M-21.9M-21.5M-20.7M-21.6M-20.8M
Cash from investing-104.0K-11.0K-153.0K-366.0K-133.0K-253.0K-64.0K-96.1K-24.7K-109.8K
Cash from financing-217.0K29.3M14.9M23.1M35.2M76.2M17.1M17.0M18.8M15.8M
Dividends paid-1.00K-1.27K
Share buybacks-207.0K35.3M1.00K1.27K17.0M18.8M16.0M
Change in cash-24.9M-3.76M-32.6M31.4M14.2M54.3M-4.41M-3.69M-2.76M-5.12M